Explore

Trendline Trendline
IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026
Trendline Trendline
Ardena Expands Executive Team to Enhance Global Growth Strategy

Ardena Expands Executive Team to Enhance Global Growth Strategy

Ardena Expands Executive Team to Enhance Global Growth Strategy
Reuters Reuters
Novo Nordisk's weight-loss pill boom faces price war test

Novo Nordisk's weight-loss pill boom faces price war test

By Maggie Fick and Stine Jacobsen LONDON/COPENHAGEN, May 5 (Reuters) - Novo Nordisk is seeing brisk early demand for its new weight-loss pill as competition with U.S. rival Eli Lilly intensifies.
Trendline Trendline
Pfizer Reaffirms 2026 Guidance Amid Strong Q1 Revenue Growth

Pfizer Reaffirms 2026 Guidance Amid Strong Q1 Revenue Growth

Pfizer Reaffirms 2026 Guidance Amid Strong Q1 Revenue Growth
Trendline Trendline
Wall Street Indexes Decline Amid Middle East Tensions and Rising Oil Prices

Wall Street Indexes Decline Amid Middle East Tensions and Rising Oil Prices

Wall Street Indexes Decline Amid Middle East Tensions and Rising Oil Prices
Trendline Trendline
ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates
Trendline Trendline
PCI Pharma Services Expands U.S. Sterile Fill/Finish Capabilities with $1 Billion Investment

PCI Pharma Services Expands U.S. Sterile Fill/Finish Capabilities with $1 Billion Investment

PCI Pharma Services Expands U.S. Sterile Fill/Finish Capabilities with $1 Billion Investment
Trendline Trendline
ESTEVE Expands in EU and USA, Strengthening Global Healthcare Presence

ESTEVE Expands in EU and USA, Strengthening Global Healthcare Presence

ESTEVE Expands in EU and USA, Strengthening Global Healthcare Presence
Trendline Trendline
UCB Acquires Candid Therapeutics for $2 Billion to Expand T-Cell Engager Therapies

UCB Acquires Candid Therapeutics for $2 Billion to Expand T-Cell Engager Therapies

UCB Acquires Candid Therapeutics for $2 Billion to Expand T-Cell Engager Therapies
Trendline Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion
Trendline Trendline
Berkshire Hathaway Reports Strong Q1 2026 Earnings Growth Driven by Insurance and Railroad Segments

Berkshire Hathaway Reports Strong Q1 2026 Earnings Growth Driven by Insurance and Railroad Segments

Berkshire Hathaway Reports Strong Q1 2026 Earnings Growth Driven by Insurance and Railroad Segments
Trendline Trendline
Moderna Exceeds Revenue Expectations Despite Litigation Costs Impacting Earnings

Moderna Exceeds Revenue Expectations Despite Litigation Costs Impacting Earnings

Moderna Exceeds Revenue Expectations Despite Litigation Costs Impacting Earnings